

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF

Art Unit: 1634

Kudaravalli, Sridhar et al.

Examiner: Pohnert, Steven C

INTERNATIONAL APPLICATION NO: PCT/EP03/10798

FILED: September 29, 2003

U.S. APPLICATION NO: 10/529613

35 USC §371 DATE: June 08, 2005

FOR: Methods for Predict Cholesterol Elevations during  
Immunosuppressant Therapy

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is being filed:

☒ supplemental to the Information Disclosure Statement filed February 27, 2009.

If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134 in the name of Novartis.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

☒ Copies of the references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

A concise explanation of the Japanese foreign language document may be found in the accompanying translation of the summary found on page 164.

Novartis Pharmaceuticals Corporation  
One Health Plaza, Bldg. 101  
East Hanover, NJ 07936  
(862) 778-9308

Date: 2/17/10

Respectfully submitted,



Leslie Fischer  
Attorney for Applicant  
Reg. No. 58,393